|
市場調查報告書
慢性骨髓性白血症：新型目標療法鎖定為Gleevec
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
|
慢性骨髓性白血症：新型目標療法鎖定為Gleevec 是由出版商Decision Resources, Inc.在2009年08月所出版的。
這份英文市場調查報告書包含22 Pages 價格從美金3450起跳。
本研究報告包括慢性骨髓性白血症的診斷與流行病學、發展等概況，以及現在及新興的治療法、2008年治療藥物銷售實績與未來展望等情報，內容摘記如下。
實施概要
序論
疾病概要
- 病因與病理生理學
- 診斷與分類
- 患者人口、症狀、病情進展
目前的治療法
- 藥物療法
- Novartis的Gllevec
- Novartis的Tasigna
- Bristol-Myers Squibb的Sprycel
- Interferon-Alpha
- 化療學名藥
- 前驅幹細胞移植
- 骨髓淨除式移植
- 異體前驅幹細胞移植
- 自體前驅幹細胞移植
新興療法
- Wyeth的Bosutinib
- Novartis的Panobinostat
- ChemGenex Pharmaceuticals的Omacetaxine Mepesuccinate
2008年統計與市場展望
圖表
Abstract
Introduction
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML
treatments garner substantial revenues. Despite recent advances in the
treatment of this disease (most notably, targeted therapeutics such as
Novartis' s Gleevec/Glivec [imatinib]), significant unmet needs remain because
certain segments of the CML patient population are intolerant of or become
resistant to existing therapies. Emerging therapies that focus on the unmet
needs of current therapeutics have a good chance of replicating Gleevec' s
success.
Questions Answered in This Report
- Properly diagnosing CML is an integral part of choosing a " n effective
treatment. How is CML diagnosed?
- What role does genetic testing play in developing and deploying drugs for
CML? What are the symptoms of CML?
- Treatment options for CML are more targeted today than in recent history.
How was CML previously treated? Why have targeted therapies proved to be
better CML treatment options?
- Despite treatment advances, opportunities remain for emerging CML agents.
What are these opportunities? Are the opportunities potentially lucrative
enough to motivate drug developers?
Scope
- Disease overview: disease causes and indicators, physical and genetic
symptoms, diagnosis, classification, epidemiology, and disease progression.
- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies,
stem cell therapy.
- Emerging CML therapies: targeted therapies, therapies focused on
particular disease mutations.
- Market outlook: 2008 CML market sales, opportunities for current and
emerging CML therapies.
Mentioned in This Report
- Bristol-Myers Squibb
- ChemGenex Pharmaceuticals
- CytRx
- Deciphera Pharmaceuticals
- Exelixis
- Genzyme Genetics
- Innate Pharma
- Janssen Pharmaceutica
- Kiadis
- Novartis
- Piramal Life Sciences
- Roche
- Schering-Plough
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Disease Overview
- Etiology and Pathophysiology
- BCR-ABL-Positive Patients
- BCR-ABL-Negative Patients
- Diagnosis and Classification
- Patient Population, Symptoms, and Disease Progression
- Current Therapies
- Drug Therapies
- Novartis' s Gleevec
- Novartis' s Tasigna
- Bristol-Myers Squibb' s Sprycel
- Interferon-Alpha
- Generic Chemotherapeutic Agents
- Progenitor Stem Cell Transplantation
- Myeloablative Regimens
- Allogenic Progenitor Stem Cell Transplantation
- Autologous Progenitor Stem Cell Transplantation
- Emerging Therapies
- Wyeth' s Bosutinib (SKI-606)
- Novartis' s Panobinostat (LBH-589)
- ChemGenex Pharmaceuticals' Omacetaxine Mepesuccinate
- 2008 Statistics and Market Outlook
Tables
- 1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia
- 2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia
- 3. Commonly Used Current Therapies in the Treatment of Chronic Myelogenous
Leukemia
- 4. Emerging Therapies for Chronic Myelogenous Leukemia
- 5. 2008 Worldwide Chronic Myelogenous Leukemia Market
Figures
- 1. The Philadelphia-Chromosome
- 2. Prevalent, Diagnosed Cases of Chronic Myelogenous Leukemia in the Major
Pharmaceutical Markets, 2008 and 2013
|
